H7 Accelerator
Empowering Healthcare Startups for Strategic Growth and Success
ABOUT H7 ACCELERATOR
H7 BioCapital offers a Once-a-Year virtual accelerator program specifically designed for healthcare companies from Seed to Series A stages. This 4-months long, equity free program features two specialized tracks: Life Science and Medtech, providing a unique opportunity to immerse in Silicon Valley and achieve strategic business objectives.
With most of the portfolios either nearing the closure of their seed round funding, or preparing for their Series A round, this program focus primarily on fundraising and partnership opportunities. Throughout the program, companies will engage in weekly one-on-one meetings with investors mentors from our extensive network of 100+ advisors. They will also pitch both in-person and virtually during Demo Day and other conference organized by H7 and our network partners.
Additionally, the Life Science track emphasizes pre-clinical and clinical development plans and licensing-out opportunities, while the Medtech track concentrates on commercializing or expanding in the U.S. market.
HIGHLIGHTS
Exceptional Quality
100+ Mentors
One-on-one mentor meetings
80+
VCs
Partnering with H7 Accelerator
Fund Raisings
Primary Focus of the Program
12+
Weeks
Virtual program
12+
Workshops
Customized to Cohorts
Free
Consultation
Tax, legal, FDA regulation, AWS credits
OUR ADVISOR NETWORK
One-on-one mentorship
Once you're selected for an accelerator cohort, you'll be part of the H7 community for life. Expand your business and expand your network with access to a talented group of founders, investors, mentors, and industry leaders.
Venture Capital
Clinical Trial
Marketing/Sales
CRO
Team Recruitment
Business Development
Manufacturing
FDA Regulations
Legal/Patent
Hospital Management
Clinician
Software Development
Finance
Science
Ella Li
Founding Partner
H7 BioCapital
Gary Goldman
Founding Partner
Global Health Impact Fund
Bill Reichert
General Partner
Pegasus Tech Ventures
Ted Hou
Founding Partner
Berkeley Catalyst Fund
Stephan Pflanz
Executive Director
Boehringer-Ingelheim Venture Fund
Neil J. Littman
Managing Director
Bioverge Ventures
INDUSTRIAL FOCUS
Cutting-edge healthcare innovations
Life Science Track
Stage: Angel to Series A
We innovate within the biotech/biopharma sectors. Our focus areas include drug discovery, personalized medicine, synthetic biology, advanced drug delivery systems, and more. Join us in advancing these cutting-edge fields to revolutionize drug development and transform healthcare.
Stage: Angel to Series A
2024 COHORT TIMELINE
Apply now
Applications Open
June 20th
Early Bird Due
July 30th
Applications Due
August 15th
Program Launch
September - December 2024
Demo Day Event
January 2025
PREVIOUS COHORT INTERVIEWS
Cutting-edge healthcare innovations